糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析
投稿时间:2018-10-10  修订日期:2018-12-29  点此下载全文
引用本文:林莉莉,姚囡囡,吴珏,刘志宏,宋洪涛.糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J].药学实践杂志,2019,37(5):473~480
摘要点击次数: 32
全文下载次数: 33
作者单位E-mail
林莉莉 沈阳药科大学生命科学与生物制药学院, 辽宁 沈阳 110016  
姚囡囡 沈阳药科大学生命科学与生物制药学院, 辽宁 沈阳 110016  
吴珏 中国人民解放军联勤保障部队第九○○医院药学科, 福建 福州 350025  
刘志宏 中国人民解放军联勤保障部队第九○○医院药学科, 福建 福州 350025  
宋洪涛 沈阳药科大学生命科学与生物制药学院, 辽宁 沈阳 110016 sohoto@vip.163.com 
中文摘要:目的 比较糠酸氟替卡松/维兰特罗复方剂(FF/VI)与吸入型糖皮质激素单药或联合长效β2受体激动剂治疗哮喘患者的疗效与耐受性差异。方法 计算机检索CNKI、PubMed、Embase、Cochrane Library等数据库,纳入随机对照试验,采用Cochrane系统评价方法进行评价。结果 共纳入10个研究,共9 811例患者。在疗效上,FF/VI组与对照组相比,提高患者的1秒用力呼气量谷值[WMD=0.09,95% CI(0.05,0.13),P=0.000]和哮喘控制测试评分[WMD=0.63,95% CI(0.24,1.03),P=0.002]。在耐受性方面,FF/VI组与对照组相比不增加患者发生与治疗相关不良反应事件风险[RR=1.15,95% CI(0.98,1.36),P=0.000]。结论 用FF/VI治疗哮喘在疗效方面具有优势,且具有良好的耐受性。其每日1次的用药频次可提高患者依从性,值得推荐使用。
中文关键词:糠酸氟替卡松  维兰特罗  吸入型糖皮质激素  长效β2受体激动剂  哮喘  荟萃分析
 
Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis
Abstract:Objective To evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol compared with ICS alone or twice-daily ICS/LABA formulations in patients with asthma.Methods Systematic search was performed for randomized controlled trials in the CNKI,PubMed,Embase and Cochrane Library.Results 10 citations contained 9 811 patients with asthma met the selection criteria. In terms of efficacy,compared with the control group,the patient's trough forced expiratory volume in one second[WMD=0.09,95% Cl(0.05,0.13) P=0.000] and asthma control Test score[WMD=0.63,95% CI(0.24,1.03),P=0.002] were increased in the FF/VI group. In terms of safety,the risk of adverse reaction events associated with treatment in patients was not increased in the FF/VI group compared to the control group[RR=1.15,95% CI(0.98,1.36),P=0.000].Conclusion FF/VI had advantages and better tolerance in treating asthma patients. It is recommended to be used for its once-daily use of the frequency,which was the advantage of improving patient adherence.
keywords:fluticasone furoate  vilanterol  ICS  LABA  asthma  Meta-analysis
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮